Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
We aimed to compare the safety of antidepressants for the treatment of persistent depressive disorder (PDD) with each other and with placebo. We conducted a systematic electronic search and included randomized controlled trials that investigated antidepressants for the treatment of PDD in adults. Outcomes were the incidence of experiencing any adverse event, specific adverse events and related treatment discontinuations. We analyzed the data using traditional and network meta-analyses. Thirty-four studies that comprised 4,769 patients and examined 20 individual agents in nine substance classes were included. Almost all analyzed substance classes were associated with higher discontinuation rates than placebo including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), antipsychotics, and the serotonin antagonist and reuptake inhibitor (SARI) trazodone. The odds of experiencing any adverse event were significantly higher for TCAs and serotonin noradrenaline reuptake inhibitors (SNRIs) compared to placebo. Pairwise comparisons among the substance classes revealed that more patients receiving TCAs or SNRIs experienced any adverse event and that more patients receiving TCAs or the SARI trazodone discontinued treatment. The complementary treatment with acetyl-l-carnitine showed lower rates of experiencing any adverse event and related discontinuations than all other comparators. TCAs were primarily associated with (anti-)cholinergic and sedating adverse events. SSRIs primarily showed gastrointestinal adverse events. Patients treated with the antipsychotic amisulpride were more likely to manifest weight gain and endocrine adverse events. The comparative evidence for further agents was insufficient or lacking. The identified safety differences may be used to inform the selection among the antidepressants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“We prepared the manuscript in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement incorporating network meta-analyses [33].”
MethodBetter Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 1×
“However, those agents should only be prescribed in exceptional cases due to their high risk of dependency [51].”
BackgroundGartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
Side effects of antidepressants during long-term use in a naturalistic setting
Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., & Hoogendijk, W. J. G. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.05.001 · Cited by 239 · cited 1×
“At the same time, persistently depressive patients mostly require a long-term treatment, during which adverse events may still be persistent [29].”
BackgroundDropouts versus completers among chronically depressed outpatients
Arnow, B. A., Blasey, C., Manber, R., Constantino, M. J., Markowitz, J. C., Klein, D. N., Thase, M. E., Kocsis, J. H., & Rush, A. J. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.06.017 · Cited by 182 · cited 1×
“With concurrent use of psychotherapy, for example, discontinuation of pharmacologic treatments may be less frequent [50].”
BackgroundBrambilla, P., Cipriani, A., Hotopf, M., & Barbui, C. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837806 · Cited by 181
Meta-analysis of rare and adverse event data
Sutton, A. J., Cooper, N. J., Lambert, P. C., Jones, D. R., Abrams, K. R., & Sweeting, M. J. (2002) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2.4.367 · Cited by 141
Kriston, L., von Wolff, A., Westphal, A., Hölzel, L. P., & Härter, M. (2014) · Depression and Anxiety · doi:10.1002/da.22236 · Cited by 119 · cited 1×
“A network meta-analysis based on the same set of primary studies like the present one revealed that among sufficiently tested agents the selective serotonin reuptake inhibitors (SSRI) fluoxetine, paroxetine, and sertraline, the monoamine oxidase inhibitor (MAO-I) moclobemide, the tricyclic antidepressant (TCA) imipram…”
MethodSelf-citation
Cited by
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
Acetyl- l -carnitine deficiency in patients with major depressive disorder
Nasca, C., Bigio, B., Lee, F. S., Young, S. P., Kautz, M. M., Albright, A., Beasley, J., Millington, D. S., Mathé, A. A., Kocsis, J. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801609115 · Cited by 152
“Previous studies showed that LAC treatment is well tolerated and effective in treatment of depressive symptoms, but these studies mainly focused on limited cohorts of elderly patients with dysthymia or fibromyalgia (13, 39, 40).”
BackgroundTherapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
Potential use of ayahuasca in grief therapy
González, D., Carvalho, M., Cantillo, J., Aixalá, M., & Farré, M. (2019) · OMEGA - Journal of Death and Dying · doi:10.1177/0030222817710879 · Cited by 44
Metadata
- Authors
- Meister, R., von Wolff, A., Mohr, H., Härter, M., Nestoriuc, Y., Hölzel, L., & Kriston, L.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-17
- Volume
- 11
- Issue
- 5
- Pages
- e0153380
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2395689204
- Cited by
- 50
- References
- 13
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.